Analysts expect Ernexa Therapeutics Inc. to report revenue of 0.00 for Q4 21, against a range of 0.00 to 0.00. The most recent reported quarter, Q3 21, came in at 0.00.
| Metric | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 |
|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | - | - | - | - | - |
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Ernexa Therapeutics Inc. to report earnings per share of -1,036.36 for Q2 22, against a range of -1,131.69 to -941.03. The most recent reported quarter, Q1 26, came in at -6.95, a 269.7% miss against the -1.88 consensus.
| Metric | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1,800.00 | -12,750.00 | -1,200.00 | -900.00 | - | - | -465.00 | -6.95 | - | - | - | - | - | - | |||||||||||||
| High Estimate | - | -592.43 | -818.98 | -1,024.75 | -941.03 | -823.94 | -854.08 | -1.77 | -3.06 | -3.39 | -4.88 | -695.00 | -692.28 | 236.27 | |||||||||||||
| Low Estimate | - | -649.93 | -925.46 | -1,220.67 | -1,131.69 | -924.68 | -1,010.10 | -1.99 | -3.34 | -3.99 | -5.20 | -842.90 | -814.82 | 198.49 | |||||||||||||
| Consensus Estimate | - | -621.18 | -872.22 | -1,122.71 | -1,036.36 | -874.31 | -932.09 | -1.88 | -3.20 | -3.69 | -5.04 | -768.95 | -753.55 | 217.38 |